OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Nuclear Medicine is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View	174
FAPI-74 PET/CT Using Either ¹⁸F-AlF or Cold-Kit ⁶⁸Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients	153
The Latest Developments in Imaging of Fibroblast Activation Protein	134
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region	129
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results	128
Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard	117
Fibroblast Activation Protein–Targeted PET/CT with ⁶⁸Ga-FAPI for Imaging IgG4-Related Disease: Comparison to ¹⁸F-FDG PET/CT	105
Impact of ⁶⁸Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas	105
Design and Development of ^99mTc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸Re Therapy	103
Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients	101
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies	93
Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an ¹⁸F-Labeled FAP Inhibitor	89
First Clinical Results for PSMA-Targeted α-Therapy Using ²²⁵Ac-PSMA-I&T in Advanced-mCRPC Patients	81
FAPI PET/CT: Will It End the Hegemony of ¹⁸F-FDG in Oncology?	78
⁶⁸Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership	74
Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from ¹⁸F-FDG PET Imaging and Neuronal Autoantibodies	73
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer	73
Diagnostic Accuracy of ¹⁸F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence	72
Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic	72
Deep-Learning ¹⁸F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma	70
Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study	70
Correlation of ⁶⁸Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study	69
Neuroinflammation PET Imaging: Current Opinion and Future Directions	68
Semiautomatically Quantified Tumor Volume Using ⁶⁸Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer	68
Head-to-Head Evaluation of ¹⁸F-FES and ¹⁸F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer	66

Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial	65
⁶⁸Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with ¹⁸F-FDG PET/CT	63
Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome	61
⁶⁸Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer	61
Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients	61
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics	61
Determining Amyloid-β Positivity Using ¹⁸F-AZD4694 PET Imaging	60
Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of	60
First-in-Human Evaluation of ¹⁸F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A	58
Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences	58
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging	57
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial	55
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of ⁶⁸Ga-Labeled FAPI Dimer	55
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET: A Pictorial Analysis	54
¹⁸F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging	54
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	54
OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry	52
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy	52
Benefit of Improved Performance with State-of-the Art Digital PET/CT for Lesion Detection in Oncology	51
First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients	50
Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients	50
Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium	50
¹⁸F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study	50
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric¹⁸F-FDG PET/CT for Oncology 1.0	49
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy	49